Project Grant K08GM166872
- The National Institute of General Medical Sciences awarded the Regents of the University of Minnesota $333,290 on March 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop a comprehensive analytical framework for integrative analysis of high-throughput biomedical data across multiple sources, dimensions, and sample cohorts. The recipient will develop flexible statistical methodology and software for bidimensional regression and factorization that...
- The National Institute of Biomedical Imaging and Bioengineering awarded the Regents of the University of Minnesota $1,364,828 on April 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to conduct research on safe, effective, and trustworthy artificial intelligence deployment across U.S. healthcare delivery organizations. The project uses mixed methods to identify barriers to and mitigation strategies for AI capability...
- The National Institute of General Medical Sciences awarded the Regents of the University of Minnesota $398,144 on April 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to engineer immunocompetent tissue models for studying inflammatory disease mechanisms. The research combines human pluripotent stem cells and genetic engineering to create microtissues containing tissue-resident macrophages with controllable inflammatory states. The project targets skeletal...
- The National Institute of Biomedical Imaging and Bioengineering awarded the Regents of the University of Minnesota $220,588 on August 25, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The award funds a three-year project to develop methodology for identifying motor phenotypes in a normative population using multimodal sensing and deep learning-based clustering. The research will collect kinematic and inertial...
- The National Institute of Biomedical Imaging and Bioengineering awarded the Regents of the University of Minnesota $471,967 on May 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The award funds development of dual density-dependent molecular AND gates—engineered targeting ligands that selectively bind cells expressing high levels of two distinct antigens via bispecific avidity. The research addresses on-target,...
- The National Science Foundation Division of Information and Intelligent Systems awarded the Regents of the University of Minnesota six hundred thousand dollars on February 1, 2026, under the Computer and Information Science and Engineering program (CFDA 47.070) to develop a federated learning framework for AI-driven diagnosis of ciliopathies and other rare genetic disorders. The project develops a privacy-preserving artificial intelligence architecture that enables collaborative model training...
- The National Institute of General Medical Sciences awarded the Regents of the University of Minnesota $404,165 on July 23, 2026, through the Biomedical Research and Research Training program (CFDA 93.859) to advance cryoimaging techniques for visualizing cellular communication mechanisms. The research applies in situ correlative cryoimaging to decode the molecular architecture of juxtacrine signaling, using the Notch pathway as a primary model system. The work aims to directly image Notch-ligand...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Minnesota $2,946,564 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to engineer immunocompetent human tissues and define inflammatory state transitions. The project develops tools to study chronic inflammation in complex human tissues by assembling immunocompetent microtissues derived from pluripotent stem cell progenitors in brain, liver, and adipose...
- The National Institute of General Medical Sciences awarded $492,931 to the Regents of the University of Minnesota on April 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop multiplexed assays of variant effect (MAVE) pipelines that integrate cellular context into synthetic protein engineering. The award funds research to advance understanding of how protein molecular traits—including folding stability and trafficking—function across different cell...
- The National Institute of General Medical Sciences awarded the Regents of the University of Minnesota $423,500 on July 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop advanced mass spectrometry platforms for assessing structural stability in biotherapeutics. The funded work will create integrated mass spectrometry methods—combining native mass spectrometry, ion mobility-mobility mass spectrometry, charge detection mass spectrometry, and controlled...
The National Institute of General Medical Sciences awarded the Regents of the University of Minnesota $200,484 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop an interoperable artificial intelligence early warning system for unrecognized in-hospital patient deterioration. The award funds transformation of the Acute Clinical Deterioration Calculator (ACDC), a machine learning model that predicts deterioration 3.4 hours earlier than current models while mitigating demographic biases, into a scalable, user-centered early warning system. The project pursues three specific aims: identifying the digital signature of unrecognized deterioration through time-series analysis of clinical interventions and martingale-based clustering techniques to detect treatment-pattern subtypes; generating end-user solutions to address known early warning system implementation barriers through qualitative analysis guided by the Theoretical Domains Framework; and refining ACDC into a scalable, user-centered early warning system through participatory design, usability testing, and standardization with HL7 FHIR. Performance occurs in Minneapolis, Minnesota, with a period of performance from September 1, 2026, through August 31, 2031. This is a project grant, a standard assistance type under NIGMS for investigator-initiated biomedical research.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $200.5k | 8/24/26 |